Reproductive factors and Parkinson's disease: A multicenter case-control study

Movement Disorders

Volumn 26, Issue 14, 2011, Pages 2563-2566

  Nicoletti, Alessandra ^a   Nicoletti, Giuseppe ^b   Arabia, Gennarina ^c   Annesi, Grazia ^b   De Mari, Michele ^d   Lamberti, Paolo ^d   Grasso, Lucia ^e   Marconi, Roberto ^e   Epifanio, Antonio ^f   Morgante, Letterio ^f   Cozzolino, Autilia ^g   Barone, Paolo ^g   Quattrone, Aldo ^b,h   Zappia, Mario ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e MISERICORDIA HOSPITAL   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h CNR   (Italy)

Author keywords

Case control study; Parkinson's disease; Reproductive factors

Indexed keywords

ESTROGEN;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FERTILE PERIOD; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; PARKINSON DISEASE; PREGNANCY; PRIORITY JOURNAL; QUESTIONNAIRE; REPRODUCTION;

AGED; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; ITALY; LEIOMYOMA; LOGISTIC MODELS; MENOPAUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; PREGNANCY; QUESTIONNAIRES; REPRODUCTION; RISK FACTORS; UTERINE NEOPLASMS;

EID: 83555177315     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23951     Document Type: Article

References (23)

1. de Lau LML, Breteler MMB. Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5: 525-535.
2. Liu B, Dluzen DE. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin Exp Pharmacol Physiol. 2007; 34: 555-565.
3. Shulman LM. Is there a connection between estrogen and Parkinson's disease? Parkinsonism. 2002; 8: 289-295.
4. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord. 2001; 16: 830-837.
5. Martignoni E, Nappi RE, Citterio A, et al. Parkinson's disease and reproductive life events. Neurol Sci. 2002; 23( Suppl 2): S85-S86.
6. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol. 2004; 61: 886-888.
7. Ragonese P, D'Amelio M, Salemi G, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology. 2004; 62: 2010-2014.
8. Popat RA, Van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology. 2005; 65: 383-390.
9. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology. 2003; 60: 790-795.
10. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology. 2008; 70; 200-209.
11. Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord. 2009; 24: 1359-1365.
12. Nicoletti A, Pugliese P, Nicoletti G, et al. The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features. Neurol Sci. 2010; 31: 47-52.
13. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999; 56: 33-39.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198
15. STATA Corp. STATA statistical software: release 10.0. College Station, TX: STATA Corporation.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967; 17: 427-442.
17. Fahn S, Elton RL, and the members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, eds. Recent Developments in Parkinson's Disease. London: MacMillan; 1987; 153-163.
18. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients: a crossover study. Neurology. 1999; 53: 91-95.
19. Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology. 2000; 54; 2292-2298
20. Shulman LM. Gender differences in Parkinson's disease.. Gend Med. 2007; 4: 8-18.
21. Nicoletti A, Arabia G, Pugliese P, et al. Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial. Clin Neuropharmacol. 2007; 30: 276-280.
22. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289: 2651-2662.
23. Nicoletti A, Pugliese P, Nicoletti G, et al. Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case-control study. Mov Disord. 2010; 25: 2387-2394.